Beam Therapeutics Inc.
BEAM
Key stats
- Open
- 25.06
- Day high
- 25.15
- Day low
- 23.86
- Previous close
- 25.81
- Volume
- 1.51M
- VWAP
- 24.45
- 52-week high
- 38.26
- 52-week low
- 20.23
- Market cap
- 2.67B
- Shares out
- 103.50M
- Employees
- 540
- Listed
- 2020
About Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · CAMBRIDGE, MA · beamtx.com
Options · expiring Nov 20
Nov 12, 4:00 PM ET- Call open interest
- 2.9K
- Put open interest
- 1.6K
- Put/call
- 0.55
- At-the-money IV
- 178.4%
| Contract | Last | Traded | Volume | Open int. | IV |
|---|---|---|---|---|---|
| 23 put | 0.49 | Nov 12, 10:30 AM | 50 | 715 | 76.9% |
| 28 call | 0.25 | Nov 10, 12:28 PM | 32 | 610 | 125.5% |
| 27 call | 0.40 | Nov 12, 3:15 PM | 16 | 143 | 72.3% |
| 22 call | 4.23 | Oct 6, 2:51 PM | 14 | 21 | 91.6% |
| 24 call | 1.49 | Nov 10, 3:44 PM | 11 | 316 | 178.4% |
| 28 put | 2.75 | Nov 3, 3:50 PM | 9 | 317 | 49.9% |
Quarterly results
Massive · Nov 3, 2026| Q3 2026 to Sep 30, 2026 | Q2 2026 to Jun 30, 2026 | Q1 2026 to Mar 31, 2026 | Q4 2025 to Dec 31, 2025 | |
|---|---|---|---|---|
| Revenue | $307.0K | $490.0K | $31.74M | $114.11M |
| Gross profit | $307.0K | $490.0K | $31.74M | $114.11M |
| Operating income | −$141.32M | −$126.76M | −$107.22M | −$17.45M |
| Net income | −$134.41M | −$122.68M | −$94.32M | $244.30M |
| Diluted EPS | -1.28 | -1.18 | -0.91 | 2.37 |
| Operating cash flow | −$110.75M | −$66.10M | −$128.51M | −$83.29M |
| Assets | $1.27B | $1.39B | $1.48B | $1.48B |
| Liabilities | $316.40M | $318.91M | $316.36M | $242.82M |
| Equity | $952.67M | $1.07B | $1.16B | $1.24B |
Technicals
Massive · Nov 12, 2026- 50-day average25.28
- 200-day average27.90
- RSI (14 days)43.8
Short interest
Massive · Oct 30, 2026- Oct 30, 202626.08M shares · 13.7 days to cover
- Oct 15, 202626.24M shares · 14.1 days to cover
- Sep 30, 202627.55M shares · 15.3 days to cover
- Sep 15, 202625.88M shares · 12.6 days to cover
Dividends
Massive · Feb 4, 2014- Ex Feb 4, 2014, paid Mar 3, 20140.2250 · 4 a year
- Ex Nov 4, 2013, paid Dec 2, 20130.2250 · 4 a year
- Ex Aug 12, 2013, paid Sep 3, 20130.2300 · 4 a year
- Ex May 6, 2013, paid Jun 3, 20130.2250 · 4 a year
- Ex Feb 4, 2013, paid Mar 1, 20130.2250 · 4 a year
- Ex Nov 5, 2012, paid Dec 3, 20120.2050 · 4 a year
- Ex Aug 6, 2012, paid Sep 4, 20120.2050 · 4 a year
- Ex May 7, 2012, paid Jun 1, 20120.2050 · 4 a year
Related companies
MassiveNews coverage
No stories about Beam Therapeutics Inc. right now.